中枢神経系(CNS)障害治療薬の世界市場2016-2020

◆英語タイトル:Global Central Nervous System Disorders Therapeutics Market 2016-2020
◆商品コード:IRTNTR10192
◆発行会社(調査会社):Technavio
◆発行日:2016年9月22日
◆ページ数:147
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、中枢神経系(CNS)障害治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、中枢神経系(CNS)障害治療薬の世界市場規模及び予測、種類別分析、用途別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About CNS disorders
CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.

Technavio’s analysts forecast the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington’s disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline
• Pfizer
• Eli Lilly
• Janssen Pharmaceuticals
• Novartis

[Other prominent vendors]
• AB Science
• AbbVie
• Abital Pharma
• Acorda Therapeutics
• Active Biotech
• Adamas Pharmaceuticals
• Addex Therapeutics
• Akorn
• Alcobra
• Alexza Pharmaceuticals
• Alkermes
• Amarantus
• Aprecia Pharmaceuticals
• Archer Pharmaceuticals
• Astellas
• AstraZeneca
• Aurobindo Pharma
• Auspex Pharmaceuticals
• Avanir Pharmaceuticals
• Biscayne Pharmaceuticals
• Boehringer Ingelheim
• Cerecor
• Concordia
• Convergence Pharmaceuticals
• Curemark
• CURx Pharmaceuticals
• Dainippon Sumitomo Pharma
• Dart NeuroScience
• Delpor
• Desitin Arzneimittel
• D-Pharm
• Edgemont Pharmaceuticals
• Endo International
• E-Therapeutics
• Euthymics
• Evotec
• F. Hoffmann-La Roche
• Fabre-Kramer Pharmaceuticals
• Forum Pharmaceuticals
• Gedeon Richter
• Glenmark
• Grupo Ferrer Internacional
• GW Pharmaceuticals
• H. Lundbeck
• Hisamitsu
• Impax
• Insero Health
• INSYS Therapeutics
• Intellipharmaceutics
• Intra-Cellular Therapies
• Ipsen
• Kyowa Hakko Kirin
• Ligand Pharmaceuticals
• Lupin
• MarcoPolo Pharmaceuticals
• Marinus Pharmaceuticals
• Meda AB
• Merck
• Mitsubishi Tanabe
• MSI Methylation Sciences
• Mylan
• Naurex
• Neuralstem
• Neurelis
• Neurovance
• Nobelpharma
• Noven Pharmaceuticals
• Omeros
• Opexa
• Opko Health
• Orion
• Ophelia Pharmaceutical
• Otsuka Pharmaceuticals
• Palobiofarma
• Par Pharmaceuticals
• Pierre Fabre
• Prana Biotechnology
• Raptor Pharmaceutical
• Reviva Pharmaceuticals
• SAGE Therapeutics
• Sanofi
• SciFlour
• Sedor Pharmaceuticals
• Shire
• Siena Biotech
• SK Biopharmaceuticals
• SOM Biotech
• Somerset Pharmaceuticals
• STADA Arzneimittel
• Sun Pharmaceuticalc
• Sunovion Pharmaceuticals
• Supernus Pharmaceuticals
• Suven
• Takeda Pharmaceuticals
• Teva Pharmaceuticals
• Torrent Pharmaceuticals
• Tris Pharma
• Turing Pharmaceuticals
• UCB
• US WorldMeds
• Valeant Pharmaceuticals
• Zinfandel Pharmaceuticals
• Zogenix

[Market driver]
• New DMD approvals for AD, PD, and MS
• For a full, detailed list, view our report

[Market challenge]
• High failure rates of late-stage products in clinical trials
• For a full, detailed list, view our report

[Market trend]
• Increased uptake of new-generation drugs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio
• Phase III pipeline portfolio: Global CNS disorders therapeutics market
• Phase II pipeline portfolio: Global CNS disorders therapeutics market
• Phase I pipeline portfolio: Global CNS disorders therapeutics market
• Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Market segmentation by type of disease
• Global depression drugs market
• Global MS drugs market
• Global schizophrenia drugs market
• Global bipolar disorder therapeutics market
• Global AD drugs market
• Global epilepsy drugs market
• Global PD drugs market

PART 08: Geographical segmentation
• CNS disorders therapeutics market in Americas
• CNS disorders therapeutics market in EMEA
• CNS disorders therapeutics market in APAC

PART 09: Market drivers
• Special regulatory designations for CNS disorders
• New DMD approvals for AD, PD, and MS
• Development of novel therapeutics using innovative technologies
• High growth potential of mAbs

PART 10: Impact of drivers

PART 11: Market challenges
• High failure rates of late-stage products in clinical trials
• Growing use of non-invasive neuromodulation and seizure management devices
• Unavailability of standard diagnostic methods
• Increase in rehabilitation programs
• Social stigma associated with CNS diseases

PART 12: Impact of drivers and challenges

PART 13: Market trends
• Popularity of me-too drugs
• Increased uptake of new-generation drugs
• Reformulation of marketed drugs
• Focus on regenerative therapies for CNS disorders
• Increase in use of LAI antipsychotics

PART 14: Vendor landscape0
• Competitive scenario0
• Key news3
• GlaxoSmithKline7
• Pfizer2
• Eli Lilly8
• Janssen Pharmaceuticals3
• Novartis8
• Other prominent vendors4

PART 15: Appendix4
• List of abbreviations4

PART 16: Explore Technavio6

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global CNS disorders therapeutics market snapshot
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Key buying criteria for CNS drugs 2015
Exhibit 05: Share of pipeline molecules in global CNS disorders therapeutics market
Exhibit 06: Prevalence of dementia in various regions (millions)
Exhibit 07: Revenues of top-selling CNS drugs (2013-2015)
Exhibit 08: Global CNS disorders therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 09: Global CNS disorders therapeutics market 2015-2020 ($ billions)
Exhibit 10: Impact of drivers and challenges on global CNS disorders therapeutics market
Exhibit 11: Five forces analysis
Exhibit 12: Global CNS disorders therapeutics market: Segmentation by application (2015-2020)
Exhibit 13: Global CNS disorders therapeutics market: Segmentation by type of disease 2015
Exhibit 14: Global CNS disorders therapeutics market segmentation: Growth cycle analysis
Exhibit 15: Global depression drugs market 2015-2020 ($ billions)
Exhibit 16: Opportunity analysis of global depression drugs market
Exhibit 17: Global MS drugs market 2015-2020 ($ billions)
Exhibit 18: Opportunity analysis of global MS drugs market
Exhibit 19: Global schizophrenia drugs market 2015-2020 ($ billions)
Exhibit 20: Opportunity analysis of global schizophrenia drugs market
Exhibit 21: Global bipolar disorder therapeutics market 2015-2020 ($ billions)
Exhibit 22: Opportunity analysis of global bipolar disorder therapeutics market
Exhibit 23: Population aged 60 years and above in millions (1950-2050)
Exhibit 24: Global AD drugs market 2015-2020 ($ billions)
Exhibit 25: Opportunity analysis of global AD drugs market
Exhibit 26: Global epilepsy drugs market 2015-2020 ($ billions)
Exhibit 27: Percentage share of marketed antiepileptic drugs based on mechanism of action
Exhibit 28: Opportunity analysis of global epilepsy drugs market
Exhibit 29: Global PD drugs market 2015-2020 ($ billions)
Exhibit 30: Opportunity analysis of global PD drugs market
Exhibit 31: Global CNS disorders therapeutics market: Geography outlook (2015-2020)
Exhibit 32: Global CNS disorders therapeutics market: Geography outlook 2015
Exhibit 33: Global CNS disorders therapeutics market segmentation by geography: Market growth lifecycle analysis 2015
Exhibit 34: Global CNS disorders market revenue/growth outlook in different countries/regions 2015
Exhibit 35: Global CNS disorders therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 36: Opportunity analysis of CNS disorders therapeutics market in Americas
Exhibit 37: Projected prevalence rates of AD in Americas (2010-2050) (millions)
Exhibit 38: CNS disorders therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 39: Percentage share of CNS disorders therapeutics market in Americas by geography 2015
Exhibit 40: Opportunity analysis of CNS disorders therapeutics market in EMEA
Exhibit 41: CNS disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 42: Opportunity analysis of CNS disorders therapeutics market in APAC
Exhibit 43: CNS disorders therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 44: Few of the late-stage mAbs under development for various CNS disorders
Exhibit 45: Impact of drivers
Exhibit 46: Common disorders that co-exist with bipolar disorder
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Impact of trends on global CNS disorders therapeutics market
Exhibit 49: Planned clinical trials of iPS cell-based therapies
Exhibit 50: Position of key vendors in the global CNS disorders therapeutics market 2015
Exhibit 51: Geographical presence of key vendors
Exhibit 52: Company portfolio analysis in global CNS disorders therapeutics market 2016-2020
Exhibit 53: GlaxoSmithKline: Profile
Exhibit 54: GlaxoSmithKline: Sales of top-selling CNS drugs ($ millions)
Exhibit 55: GlaxoSmithKline: Metrics analysis
Exhibit 56: GlaxoSmithKline: Growth strategy matrix
Exhibit 57: GlaxoSmithKline: Opportunity assessment
Exhibit 58: Pfizer: Profile
Exhibit 59: Sales of CNS drugs ($ millions)
Exhibit 60: Pfizer: Metrics analysis
Exhibit 61: Pfizer: Growth strategy matrix
Exhibit 62: Pfizer: Opportunity assessment
Exhibit 63: Eli Lilly: Profile
Exhibit 64: Eli Lilly: Sales of top-selling CNS drugs ($ millions)
Exhibit 65: Eli Lilly: Metrics analysis
Exhibit 66: Eli Lilly: Growth strategy matrix
Exhibit 67: Eli Lilly: Opportunity assessment
Exhibit 68: Janssen Pharmaceuticals: Profile
Exhibit 69: Janssen Pharmaceuticals: Sales of CNS drugs ($ millions)
Exhibit 70: Janssen Pharmaceuticals: Metrics analysis
Exhibit 71: Janssen Pharmaceuticals: Growth strategy matrix
Exhibit 72: Janssen Pharmaceuticals: Opportunity assessment
Exhibit 73: Novartis: Profile
Exhibit 74: Novartis: Sales of few major CNS drugs ($ millions)
Exhibit 75: Novartis: Metrics analysis
Exhibit 76: Novartis growth strategy matrix
Exhibit 77: Novartis: Opportunity assessment



【掲載企業】

GlaxoSmithKline, Pfizer, Eli Lilly, Janssen Pharmaceuticals, and Novartis.

Other Prominent Vendors in the market are: AB Science, AbbVie, Abital Pharma, Acorda Therapeutics, Active Biotech, Adamas Pharmaceuticals, Addex Therapeutics, Akorn, Alcobra, Alexza Pharmaceuticals, Alkermes, Amarantus, Aprecia Pharmaceuticals, Archer Pharmaceuticals, Astellas, AstraZeneca, Aurobindo Pharma, Auspex Pharmaceuticals, Avanir Pharmaceuticals, Biscayne Pharmaceuticals, Boehringer Ingelheim, Cerecor, Concordia, Convergence Pharmaceuticals, Curemark, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, Dart NeuroScience, Delpor, Desitin Arzneimittel, D-Pharm, Edgemont Pharmaceuticals, Endo International, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre-Kramer Pharmaceuticals, Forum Pharmaceuticals, Gedeon Richter, Glenmark, Grupo Ferrer Internacional, GW Pharmaceuticals, H. Lundbeck, Hisamitsu, Impax, Insero Health, INSYS Therapeutics, Intellipharmaceutics, Intra-Cellular Therapies, Ipsen, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Lupin, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda AB, Merck, Mitsubishi Tanabe, MSI Methylation Sciences, Mylan, Naurex, Neuralstem, Neurelis , Neurovance, Nobelpharma, Noven Pharmaceuticals, Omeros, Opexa, Opko Health, Orion, Ophelia Pharmaceutical, Otsuka Pharmaceuticals, Palobiofarma, Par Pharmaceuticals, Pierre Fabre, Pierre Fabre, Prana Biotechnology, Raptor Pharmaceutical, Reviva Pharmaceuticals , SAGE Therapeutics, Sanofi, SciFlour, Sedor Pharmaceuticals, Shire, Siena Biotech, SK Biopharmaceuticals, SOM Biotech, Somerset Pharmaceuticals, STADA Arzneimittel, Sun Pharmaceuticalc, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Suven, Takeda Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Tris Pharma, Turing Pharmaceuticals, UCB, US WorldMeds, Valeant Pharmaceuticals, Zinfandel Pharmaceuticals, and Zogenix.

【レポートのキーワード】

中枢神経系障害、CNS障害、治療薬、医薬品、うつ病治療薬、統合失調症治療薬、MS薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[中枢神経系(CNS)障害治療薬の世界市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月04日現在 219,162 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆